Brought to you by 
Celltech Chiroscience PLC acquires Medeva PLC for $914mm
04 Jan 2000
Executive Summary
In a stock swap, Celltech Chiroscience PLC (CCP) has acquired competitor Medeva PLC, exchanging 34 of its shares for every 100 Medeva shares held. Based on CCP's closing price of $7.87 the day before the announcement, it is paying $2.67 per share of Medeva, representing about a (pr)16% premium to Medeva's pre-announcement price,valuing the transaction at $914mm (UK563mm). CCP shareowners will hold 56% of the combined entity--which will be called the Celltech Group PLC--with Medeva holding the rest. Peter Fellner, Celltech's CEO, will serve in the same capacity at the new company, which will have a $2.1bn pro-forma market cap.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Celltech Chiroscience PLC acquires Medeva PLC for $914mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice